Doxycare Flavour 40 mg Tablets for Cats and Dogs

Country: Իռլանդիա

language: անգլերեն

source: HPRA (Health Products Regulatory Authority)

active_ingredient:

Doxycycline hyclate

MAH:

Ecuphar NV

ATC_code:

QJ01AA02

INN:

Doxycycline hyclate

dosage:

40 mg/tablet

pharmaceutical_form:

Tablet

prescription_type:

POM: Prescription Only Medicine as defined in relevant national legislation

therapeutic_area:

doxycycline

authorization_status:

Authorised

authorization_date:

2019-10-25

SPC

Health Products Regulatory Authority
13 January 2022
CRN00CM0V
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Doxycare Flavour 40 mg Tablets for Cats and Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
Active substance:
​
Doxycycline
​40 mg
(equivalent to 47.88 mg of doxycycline hyclate)
Excipients:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablet
Yellowish, round and convex tablet with a cross-shaped break line on
one side.
Tablets can be divided into 2 or 4 equal parts.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cats and dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Dogs
For the treatment of respiratory tract infections including rhinitis,
tonsillitis and bronchopneumonia caused by _Bordetella _
_bronchiseptica_, and _Pasteurella_ spp susceptible to doxycycline.
_ _
For the treatment of canine ehrlichiosis caused by _Ehrlichia canis_.
Cats
For the treatment of respiratory tract infections including rhinitis,
tonsillitis and bronchopneumonia caused by _Bordetella _
_bronchiseptica_, and _Pasteurella_ spp susceptible to doxycycline.
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use in animals with renal or hepatic insufficiency.
Do not use in animals with diseases associated with vomiting or
dysphagia (see also section 4.6).
Do not use in animals with known photosensitivity (see also section
4.6).
Do not use in puppies and kittens before completion of teeth enamel
formation.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
_Ehrlichia canis_ infection: treatment should be initiated at the
onset of clinical signs. Complete eradication of the pathogen is
not always achieved, but treatment for 28 days generally leads to a
resolution of the clinical signs and a reduction of the
bacterial load. A longer duration of treatment, based on a
benefit/risk assessment by the responsible veterinarian, may be
required particularly in severe or chro